Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Morphosys Ag ADR (MPSYY)

Morphosys Ag ADR (MPSYY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Morphosys Ag ADR

Description:

MorphoSys AG was founded in July 1992 as a German limited liability company. In June 1998, MorphoSys became a German stock corporation. In March 1999, the Company completed its initial public offering on Germany's "Neuer Markt", the segment of the Deutsche Borse designated for growth companies. The company and its subsidiaries develops and commercializes antibodies for therapeutic applications. It also develops drugs together with its partners in the pharmaceutical and biotechnology industries and through its proprietary development activities, which includes Celgene, GlaxoSmithKline and Heptares. The Company operates in two segments; Partnered Discovery and Proprietary Development. The Partnered Discovery segment operates therapeutic development programs for drug candidates in cooperation with renowned biotechnology and pharmaceutical companies. In this segment, the Company works together with its partners on solutions for the urgent health issues. The Partnered Discovery segment uses Company's technologies for the research, development, and optimization of therapeutic antibodies as drug candidates in extensive partnerships with pharmaceutical and biotechnology companies. Proprietary therapeutic antibodies are currently being developed in the second segment Proprietary Development. It has developed a number of technologies that offers direct access to fully human antibodies for the treatment of diseases. Its widely-known technologies include HuCAL, which is a collection of billions of fully human antibodies. The Company competes with a number of companies in the field of therapeutic antibody development and in the out-licensing of clinical development candidates. In the case of partnered programs, the partner companies files patent applications for individual drugs in cooperation with the Company's patent department.

Key Statistics

Overview:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return 65.36%
3-Year Return 77.56%
5-Year Return 0.00%

Per-Share Information:

Latest Earnings Date N/A
Dividend Payout Ratio 0.00%

MPSYY Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 5.73
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar